Arcus Biosciences
RCUS
RCUS
179 hedge funds and large institutions have $1.01B invested in Arcus Biosciences in 2023 Q1 according to their latest regulatory filings, with 24 funds opening new positions, 70 increasing their positions, 60 reducing their positions, and 43 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more ownership
Funds ownership: →
less capital invested
Capital invested by funds: $ → $
11% less funds holding
Funds holding: 200 → 179 (-21)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
44% less first-time investments, than exits
New positions opened: 24 | Existing positions closed: 43
Holders
179
Holding in Top 10
3
Calls
$10.2M
Puts
$7.43M
Top Buyers
| 1 | +$35.6M | |
| 2 | +$20.5M | |
| 3 | +$18.4M | |
| 4 |
BlackRock
New York
|
+$13.7M |
| 5 |
Walleye Capital
New York
|
+$7.58M |
Top Sellers
| 1 | -$47.6M | |
| 2 | -$24.8M | |
| 3 | -$20.9M | |
| 4 |
FAM
Fred Alger Management
New York
|
-$10.5M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$8.8M |